Skip to main content

123 - References

References

118 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 1 Rectal Chlorpromazine suppositories are available from specials manufacturers in the UK in 25mg and 100mg strengths.21 The rectal route is not licensed in adults.17 100mg given rectally as a suppository is approximately equivalent to 20–25mg chlorpromazine hydrochloride given by IM injection or 40–50mg of chlorpromazine base or hydrochloride given orally.17 Prochlorperazine suppositories were used successfully short term for the treatment of psychosis in one case report.22 Olanzapine suppositories have been manufactured by a hospital pharmacy and administered for the treatment of delirium or nausea and vomiting in terminally ill patients.23 References

  1. Katare YK, et al. Intranasal delivery of antipsychotic drugs. Schizophr Res 2017; 184:2–13.
  2. Majcher MJ, et al. In situ-­gelling starch nanoparticle (SNP)/O-­carboxymethyl chitosan (CMCh) nanoparticle network hydrogels for the intranasal delivery of an antipsychotic peptide. J Control Release 2021; 330:738–752.
  3. Pandey M, et al. Advances and challenges in intranasal delivery of antipsychotic agents targeting the central nervous system. Front Pharmacol 2022; 13:865590.
  4. Pires PC, et al. Antipsychotics-­loaded nanometric emulsions for brain delivery. Pharmaceutics 2022; 14:2174.
  5. Miller JL, et al. Comparison of intranasal administration of haloperidol with intravenous and intramuscular administration: a pilot pharmacokinetic study. Pharmacotherapy 2008; 28:875–882.
  6. Cooper I, et al. The pharmacokinetics of intranasal droperidol in volunteers characterised via population modelling. SAGE Open Med 2018; 6:2050312118813283.
  7. Bleck TP. Dopamine antagonists in ICU delirium. N Engl J Med 2018; 379:2569–2570.
  8. Smit L, et al. Efficacy of haloperidol to decrease the burden of delirium in adult critically ill patients: the EuRIDICE randomized clinical trial. Crit Care 2023; 27:413.
  9. Beach SR, et al. Intravenous haloperidol: a systematic review of side effects and recommendations for clinical use. Gen Hosp Psychiatry 2020; 67:42–50.
  10. Khorassani F, et  al. Intravenous olanzapine for the management of agitation: review of the literature. Ann Pharmacother 2019; 53:853–859.
  11. Wilson IC, et al. A double-­blind trial to investigate the effects of Thorazine (Largactil, chlorpromazine), Compazine (Stemetil, prochlorperazine) and Stelazine (trifluoperazine) in paranoid schizophrenia. J Ment Sci 1961; 107:90–99.
  12. Kostic MA, et al. A prospective, randomized trial of intravenous prochlorperazine versus subcutaneous sumatriptan in acute migraine therapy in the emergency department. Ann Emerg Med 2010; 56:1–6.
  13. Kaminsky BM, et  al. Alternate routes of administration of antidepressant and antipsychotic medications. Ann Pharmacother 2015; 49:808–817.
  14. Karlin DM, et  al. Dexmedetomidine sublingual film: a new treatment to reduce agitation in schizophrenia and bipolar disorders. Ann Pharmacother 2024; 58:54–64.
  15. Citrome L, et al. Sublingual dexmedetomidine for the treatment of acute agitation in adults with schizophrenia or schizoaffective disorder: a randomized placebo-­controlled trial. J Clin Psychiatry 2022; 83:22m14447.
  16. Fernando T, et  al. Buccally absorbed vs intravenous prochlorperazine for treatment of migraines headaches. Acta Neurol Scand 2019; 140:72–77.
  17. National Institute for Health and Care Excellence. British National Formulary (BNF). 2024; https://bnf.nice.org.uk.
  18. Citrome L, et al. Patches: established and emerging transdermal treatments in psychiatry. J Clin Psychiatry 2019; 80:18nr12554.
  19. Abruzzo A, et al. Transdermal delivery of antipsychotics: rationale and current status. CNS Drugs 2019; 33:849–865.
  20. El-­Tokhy FSe, et al. Transdermal delivery of second-­generation antipsychotics for management of schizophrenia; disease overview, conventional and nanobased drug delivery systems. J Drug Delivery Sci Technol 2021; 61:102104.
  21. National Health Service UK. dm+d browser. 2024; https://dmd-­browser.nhsbsa.nhs.uk.
  22. Servis M, et al. Treatment of psychosis with prochlorperazine in the ICU setting. Psychosomatics 1997; 38:589–590.
  23. Matsumoto K, et al. Pharmaceutical studies on and clinical application of olanzapine suppositories prepared as a hospital preparation. J Pharm Health Care Sci 2016; 2:20.

No comments to display

Back to top